2020 Revenues ($USD) : $3,122,035,962 2020 Revenues (foreign currencies) : JP¥333,371,000,000 2020 R&D spend : $449,044,765 2020 Number of Employees : 5,233 Fiscal Year End : 3/31/2020 Key People : Isao Teshirogi, president & CEO
Shionogi is more than 140 years old. The Japanese pharma giant is focusing in the U.S. on developing and commercializing products to meet what it sees as unmet needs, including infectious diseases, pain and chronic liver disease. Shionogi in 2020 launched the siderophore cephalosporin antibiotic Fetroja (cefiderocol) in the U.S. –CN